|By PR Newswire||
|March 28, 2014 12:20 PM EDT||
LONDON, March 28, 2014 /PRNewswire/ --
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
On Thursday, shares in Prana Biotechnology Ltd declined 5.81% to close the trading session at $9.89. The stock recorded a trading volume of 1.92 million shares, as compared with a three months average volume of 2.06 million shares. Shares in the company oscillated between $8.80 and $10.36 during the trading session. Prana Biotechnology Ltd's shares have declined 11.54% in the previous three trading sessions and 14.22% in the last month, while the same have surged 41.08% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Prana Biotechnology Ltd's 50-day moving average of $9.76 is above its 200-day moving average of $5.68. Furthermore, the stock is has a Relative Strength Index (RSI) of 52.79. Sign up today to read free research on PRAN at:
Amarin Corp PLC's stock recorded a trading volume of 2.74 million shares, as compared with a three months average volume of 5.00 million shares. The stock ended the day at $1.85, up 5.71% after vacillating between $1.71 and $1.85. Amarin Corp PLC's shares have gained 5.11% in the previous three trading sessions and 3.93% in the last one month, while the same have declined 6.09% on YTD basis. The company's stock is trading above its 50-day moving average. Amarin Corp PLC's 200-day moving average of $3.75 is above its 50-day moving average of $1.83. Additionally, shares of the company have an RSI of 44.75. Sign up today to read free research on AMRN at:
On Thursday, shares in United Therapeutics Corp. finished the session 0.26% higher at $93.86. A total of 1.06 million shares were traded, which is above the three months average volume of 0.76 million. The stock fluctuated between $91.34 and $95.57 during the session. Shares of the company traded at a PE ratio of 28.62. United Therapeutics Corp.'s stock fell 0.27% in the previous three trading sessions, 8.21% in the last one month, and 17.00% on YTD basis. The stock is trading above its 200-day moving average. United Therapeutics Corp.'s 50-day moving average of $101.57 is above its 200-day moving average of $86.57. Moreover, the stock indicated an RSI 37.64. Sign up today to read free research on UTHR at:
Shares in OPKO Health Inc. reported a trading volume of 2.14 million shares, as compared with a three months average volume of 3.13 million shares. The stock ended the day at $9.05, down 0.33% and at an intraday range of $8.88 and $9.24. OPKO Health Inc.'s shares have fallen by 2.58% in the previous three trading sessions and 3.21% in the last month, but they have gained 7.23% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. OPKO Health Inc.'s 200-day moving average of $8.82 is above its 50-day moving average of $8.79. Furthermore, the stock indicated an RSI of 46.82. Sign up today to read free research on OPK at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.